Captrust Financial Advisors Has $7.84 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Captrust Financial Advisors lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 119,690 shares of the company’s stock after selling 17,443 shares during the quarter. Captrust Financial Advisors’ holdings in AstraZeneca were worth $7,842,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cibc World Markets Corp raised its position in shares of AstraZeneca by 1.1% in the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company’s stock valued at $845,000 after buying an additional 142 shares in the last quarter. Diversify Wealth Management LLC increased its holdings in AstraZeneca by 3.6% in the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after buying an additional 153 shares during the period. Veery Capital LLC raised its position in shares of AstraZeneca by 4.7% in the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after buying an additional 157 shares in the last quarter. Tiller Private Wealth Inc. lifted its holdings in shares of AstraZeneca by 5.7% during the 4th quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company’s stock worth $219,000 after acquiring an additional 181 shares during the period. Finally, Dorsey & Whitney Trust CO LLC boosted its position in shares of AstraZeneca by 0.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock worth $2,313,000 after acquiring an additional 189 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. BNP Paribas started coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective on the stock. Finally, Morgan Stanley began coverage on AstraZeneca in a research note on Wednesday, February 12th. They set an “overweight” rating for the company. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca has an average rating of “Buy” and an average price target of $88.00.

AstraZeneca Stock Performance

Shares of AZN stock opened at $67.30 on Friday. The business’s 50-day moving average price is $71.53 and its 200-day moving average price is $69.81. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $208.71 billion, a price-to-earnings ratio of 29.78, a PEG ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.06 EPS. Equities research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.